Effect of the signaling lymphocytic activation molecule (SLAM) in the modulation of T cells in immune response to Leishmania braziliensis in vitro / Efeito da molécula de sinalização para ativação linfocítica (SLAM) na modulação de células T na resposta imune à Leishmania braziliensis in vitro

Introduction: Signaling lymphocyte activation molecule (SLAM) is a self-ligand receptor on the surface of activated T- and B-lymphocytes, macrophages, and DC. Studies have shown PBMC from healthy individuals exposed to Leishmania differ in IFN-γ production. Objective: We investigated the role of SLAM signaling pathway in PMBC from high (HP) and low (LP) IFN-γ producers exposed to L. braziliensis in vitro. Methods: PBMC from 43 healthy individuals were cultured with or without antigen, α-SLAM, rIL-12 and rIFN-γ. The cytokines production was evaluated by ELISA, and SLAM expression by flow cytometry. Results: L. braziliensis associated with rIFN-γ or rIL-12 reduced early SLAM but did not modify this response later in HP. α-SLAM did not alter CD3+SLAM+ expression, and not affected IFN-γ and IL-13 production, in both groups, but increased significantly IL-10 in HP. Leishmania associated with α-SLAM and rIL-12 increased IFN-γ in LP, as well as IL-13 in HP. LP group presented low IFN-γ and IL-13 production, and low SLAM expression. Conclusion: Collectively, these findings suggest that when PBMC from healthy individuals are sensitized with L. braziliensis in vitro, SLAM acts in modulating Th1 response in HP individuals and induces a condition of immunosuppression in LP individuals. (AU)

Introdução: A molécula de sinalização para ativação linfocítica (SLAM) é um receptor autoligante na superfície de linfócitos T e B ativados, macrófagos e DC. Estudos têm mostrado que PBMC de indivíduos saudáveis expostos à Leishmania diferem na produção de IFN-γ. Objetivo: Nós investigamos o papel da via de sinalização de SLAM em PMBC de altos produtores de IFN-γ (AP) e baixos (BP) expostos à L. braziliensis in vitro. Métodos: PBMC de 43 indivíduos saudáveis foram cultivadas com ou sem antígeno, α-SLAM, rIL-12 e rIFN-γ. Foi avaliada a produção de citocinas por ELISA e expressão de SLAM por citometria de fluxo. Resultados: L. braziliensis associado a rIFN-γ ou rIL-12 reduziu a expressão inicial de SLAM, mas não modificou esta resposta mais tarde em AP. α-SLAM não alterou a expressão de CD3+SLAM+, e não afetou a produção de IFN-γ e IL-13, em ambos os grupos, mas aumentou significativamente IL-10 em AP. Leishmania associada a α-SLAM e rIL-12 aumentou IFN-γ em BP, assim como IL-13 em AP. BP apresentaram baixa produção de IFN-γ e IL-13 e baixa expressão de SLAM. Conclusão: Coletivamente, esses achados sugerem que quando PBMC de indivíduos saudáveis são sensibilizados por L. braziliensis in vitro, SLAM atua na modulação da resposta Th1 em indivíduos AP e induz uma condição de imunossupressão em indivíduos BP. (AU)

A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia.

BACKGROUND: Acute lymphoblastic leukemia is the most common malignant cancer in childhood. The signs and symptoms of childhood cancer are difficult to recognize, as it is not the first diagnosis to be considered for nonspecific complaints, leading to potential uncertainty in diagnosis. The aim of this study was to perform proteomic analysis of serum from pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) to identify candidate biomarker proteins, for use in early diagnosis and evaluation of treatment. METHODS: Serum samples were obtained from ten patients at the time of diagnosis (B-ALL group) and after induction therapy (AIT group). Sera from healthy children were used as controls (Control group). The samples were subjected to immunodepletion, affinity chromatography with α-d-galactose-binding lectin (from Artocarpus incisa seeds) immobilized on a Sepharose(TM) 4B gel, concentration, and digestion for subsequent analysis with nano-UPLC tandem nano-ESI-MS(E). The program Expression (E) was used to quantify differences in protein expression between groups. RESULTS: A total of 96 proteins were identified. Leucine-rich alpha-2-glycoprotein 1 (LRG1), Clusterin (CLU), thrombin (F2), heparin cofactor II (SERPIND1), alpha-2-macroglobulin (A2M), alpha-2-antiplasmin (SERPINF2), Alpha-1 antitrypsin (SERPINA1), Complement factor B (CFB) and Complement C3 (C3) were identified as candidate biomarkers for early diagnosis of B-ALL, as they were upregulated in the B-ALL group relative to the control and AIT groups. Expression levels of the candidate biomarkers did not differ significantly between the AIT and control groups, providing further evidence that the candidate biomarkers are present only in the disease state, as all patients achieved complete remission after treatment. CONCLUSION: A panel of protein biomarker candidates has been developed for pre-diagnosis of B-ALL and also provided information that would indicate a favorable response to treatment after induction therapy.